Arcutis Biotherapeutics, Inc.

NasdaqGS:ARQT 株式レポート

時価総額：US$999.0m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Arcutis Biotherapeutics マネジメント

マネジメント 基準チェック /24

Arcutis Biotherapeutics'の CEO はFrank Watanabeで、 Jan2016年に任命され、 の在任期間は 8.42年です。 の年間総報酬は$ 4.94Mで、 12.8%給与と87.2%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.54%を直接所有しており、その価値は$ 5.38M 。経営陣と取締役会の平均在任期間はそれぞれ2.5年と4.1年です。

主要情報

Frank Watanabe

最高経営責任者

US$4.9m

報酬総額

CEO給与比率12.8%
CEO在任期間8.4yrs
CEOの所有権0.5%
経営陣の平均在職期間2.5yrs
取締役会の平均在任期間4.1yrs

経営陣の近況

Recent updates

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

May 24
Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory

May 20

Arcutis Biotherapeutics: Betting Big On Zoryve

May 01

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Apr 25
New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Mar 03
Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Mar 02
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Feb 28
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Jan 31

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

Oct 23
Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Aug 13
Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57

Aug 11
Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57

Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

May 02
Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Dec 18
Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Arcutis sees positive top-line results from roflumilast in scalp and body psoriasis

Sep 26

Arcutis Biotherapeutics: A Name To Accumulate

Sep 18

Arcutis acquires privately-held biotech Ducentis BioTherapeutics

Sep 07

CEO報酬分析

Arcutis Biotherapeutics の収益と比較して、Frank Watanabe の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$217m

Dec 31 2023US$5mUS$634k

-US$262m

Sep 30 2023n/an/a

-US$268m

Jun 30 2023n/an/a

-US$331m

Mar 31 2023n/an/a

-US$327m

Dec 31 2022US$5mUS$590k

-US$311m

Sep 30 2022n/an/a

-US$311m

Jun 30 2022n/an/a

-US$260m

Mar 31 2022n/an/a

-US$235m

Dec 31 2021US$4mUS$525k

-US$206m

Sep 30 2021n/an/a

-US$169m

Jun 30 2021n/an/a

-US$150m

Mar 31 2021n/an/a

-US$144m

Dec 31 2020US$3mUS$442k

-US$136m

Sep 30 2020n/an/a

-US$114m

Jun 30 2020n/an/a

-US$90m

Mar 31 2020n/an/a

-US$63m

Dec 31 2019US$1mUS$390k

-US$42m

Sep 30 2019n/an/a

-US$35m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$634kUS$327k

-US$19m

報酬と市場: Frankの 総報酬 ($USD 4.94M ) は、 US市場 ($USD 3.37M ) の同規模の企業の平均を上回っています。

報酬と収益: Frankの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Frank Watanabe (56 yo)

8.4yrs

在職期間

US$4,935,266

報酬

Mr. Todd Franklin Watanabe, also known as Frank, M.A., serves as Director of Amunix Pharmaceuticals, Inc. since June 2021. He has been President of Arcutis Biotherapeutics, Inc. (Formerly known as Arcutis...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Todd Watanabe
President8.4yrsUS$4.94m0.54%
$ 5.4m
Bhaskar Chaudhuri
Co-Founder & Independent Directorno dataUS$153.74k0.77%
$ 7.7m
Patrick Burnett
Senior VP & Chief Medical Officer3.8yrsUS$1.67m0%
$ 0
L. Edwards
Senior VP & Chief Commercial Officerless than a yearUS$2.03mデータなし
David Topper
Senior VP & Chief Financial Officerless than a yearデータなしデータなし
Rajvir Madan
Chief Digital & Technology Officer2.7yrsデータなしデータなし
Latha Vairavan
Vice President of Finance & Investor Relationsno dataデータなしデータなし
Courtney Barton
VP and Chief Compliance Officer & Privacy Officer3.3yrsデータなしデータなし
Masaru Matsuda
Senior VP2.4yrsUS$5.14m0.015%
$ 152.9k
Amanda Sheldon
Head of Corporate Communications2.8yrsデータなしデータなし
Ayisha Jeter
Head of Marketing & Market Accessless than a yearデータなしデータなし
Kent Taylor
Vice President of Sales1.4yrsデータなしデータなし

2.5yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: ARQTの経営陣は 経験豊富 であると考えられます ( 2.5年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Todd Watanabe
President7.4yrsUS$4.94m0.54%
$ 5.4m
Bhaskar Chaudhuri
Co-Founder & Independent Director8.2yrsUS$153.74k0.77%
$ 7.7m
Patrick Heron
Independent Chairman of the Board8.2yrsUS$181.24k0.024%
$ 241.7k
Mark Lebwohl
Scientific Advisorno dataデータなしデータなし
Lawrence F. Eichenfield
Scientific Advisorno dataデータなしデータなし
Kim Papp
Scientific Advisorno dataデータなしデータなし
Terrie Curran
Independent Director3.6yrsUS$148.74k0.0037%
$ 37.2k
Halley Gilbert
Independent Director4.1yrsUS$148.74k0.0037%
$ 37.2k
Howard Welgus
Director3.8yrsUS$144.24k0.17%
$ 1.7m
Sue-Jean Lin
Independent Director3yrsUS$163.74k0.0040%
$ 39.8k
M Rico
Scientific Advisorno dataデータなしデータなし
Matt Zirwas
Scientific Advisorno dataデータなしデータなし

4.1yrs

平均在職期間

60.5yo

平均年齢

経験豊富なボード: ARQTの 取締役会 は 経験豊富 であると考えられます ( 4.1年の平均在任期間)。